Halozyme insider plans stock sales via Form 144

Halozyme Therapeutics filed a Form 144 indicating an affiliate’s intent to sell common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services group at 1 New York Plaza, New York.

Accepted by SEC EDGAR 08/11/2026 - 05:57 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Halozyme Therapeutics filed a Form 144 indicating an affiliate’s intent to sell common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services group at 1 New York Plaza, New York. The notice reflects planned cash sales tied to stock option exercises on August 11, 2026, including transactions for 32,659, 5,277, and 3,766 shares of common stock.

Key Figures

Stock option exercise sale 1: 32,659 shares Stock option exercise sale 2: 5,277 shares Stock option exercise sale 3: 3,766 shares

3 metrics

Stock option exercise sale 1 32,659 shares Common stock transaction dated 08/11/2026 for cash

Stock option exercise sale 2 5,277 shares Common stock transaction dated 08/11/2026 for cash

Stock option exercise sale 3 3,766 shares Common stock transaction dated 08/11/2026 for cash

Key Terms

Form 144, stock option exercise, Executive Financial Services

3 terms

Form 144 regulatory

"Halozyme Therapeutics filed a Form 144 indicating an affiliate’s intent"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

stock option exercise financial

"planned cash sales tied to stock option exercises on August 11, 2026"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services group"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Halozyme Therapeutics (HALO) disclose in this Form 144?

Halozyme Therapeutics discloses a planned sale of common stock by an affiliate, to be executed through Morgan Stanley Smith Barney LLC’s Executive Financial Services unit in connection with stock option exercises on August 11, 2026.

Which broker is involved in the HALO Form 144 stock sale?

The Form 144 lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the broker handling the proposed sales of Halozyme Therapeutics common stock.

What type of Halozyme (HALO) securities are covered by this Form 144?

The filing covers common stock of Halozyme Therapeutics. The planned transactions are linked to stock option exercises, with the consideration described as cash for the sales noted for August 11, 2026.

What stock option exercise activity is reported for HALO on August 11, 2026?

The Form 144 reports three stock option exercise-related transactions on August 11, 2026, for 32,659, 5,277, and 3,766 shares of Halozyme Therapeutics common stock, each described as cash transactions with the issuer as counterparty.

Does the Halozyme (HALO) Form 144 describe sales during the past 3 months?

The document includes a section labeled “Securities Sold During The Past 3 Months”, but the key details emphasized relate to planned stock option exercise-related sales dated August 11, 2026, rather than a detailed historical sales breakdown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002090209
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	HALOZYME THERAPEUTICS, INC.
SEC File Number	001-32335
Address of Issuer	12390 EL CAMINO REAL SAN DIEGO CALIFORNIA 92130
Phone	(858) 794-8889
Name of Person for Whose Account the Securities are To Be Sold	CORTNEY A CAUDILL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	41702	4302349.47	113498000	08/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2026	Stock Option Exercise	Issuer			32659	08/11/2026	Cash
Common	08/11/2026	Stock Option Exercise	Issuer			5277	08/11/2026	Cash
Common	08/11/2026	Stock Option Exercise	Issuer			3766	08/11/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Cortney Caudill
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)